Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 4552-4556, October 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sturm, R. J.
Right arrow Articles by Carchman, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sturm, R. J.
Right arrow Articles by Carchman, R. A.

Antagonist of Phorbol Ester Receptor-mediated Chemotaxis in Mouse Peritoneal Macrophages1

Robert J. Sturm2, Bonita M. Smith3, Richard W. Lane3, Debra L. Laskin4, Louis S. Harris and Richard A. Carchman5

Department of Pharmacology and Toxicology, Medical College of Virginia, Richmond, Virginia 23298

Biologically active phorbol ester derivatives displace [3H]phorbol-12,13-dibutyrate from thioglycollate-elicited mouse peritoneal macrophages in a time-, temperature-, and concentration-dependent manner. Scatchard analysis revealed an apparent Kd of 54.1 nM and 8.0 x 105 sites/cell, indicating that these macrophages possess saturable, high-affinity phorbol ester-binding sites. These derivatives also act as chemoattractants for the macrophage at equivalent concentrations. A notable exception to this pattern is phorbol-12,13-diacetate. Phorbol-12,13-diacetate inhibits specific binding of [3H]phorbol-12,13-dibutyrate (concentration required for a 50% inhibition of the maximum specific binding of [3H]phorbol-12,13-dibutyrate, 2.6 µM) and chemotaxis to phorbol-12-myristate, 13-acetate (concentration required for a 50% inhibition of the maximum chemotactic response, 0.39 µM) while exhibiting no activity as a chemoattractant at concentrations up to 10-5 M. The data indicate that phorbol-12,13-diacetate may be an antagonist for receptor-mediated chemotaxis to phorbol-12-myristate, 13-acetate in the macrophage.

1 Supported by grants from the American Cancer Society (IN-105G), the National Institute of Dental Research (5P50DE05139) and the United States Environmental Protection Agency (R-808861010).

2 Postdoctoral trainee supported by National Institute of Environmental Health Services Training Grant T32E507087. To whom requests for reprints should be addressed.

3 Predoctoral trainees supported by National Institute of Environmental Health Services Training Grant T32E507087.

4 Present address: The Wistar Institute of Anatomy and Biology, Philadelphia, Pa. 19104.

5 Recipient of NIH Research Career Development Award K04AM00565.

Received 9/ 8/82. Accepted 7/ 1/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.